[go: up one dir, main page]

EA201991607A1 - Генетически модифицированные клетки-натуральные киллеры - Google Patents

Генетически модифицированные клетки-натуральные киллеры

Info

Publication number
EA201991607A1
EA201991607A1 EA201991607A EA201991607A EA201991607A1 EA 201991607 A1 EA201991607 A1 EA 201991607A1 EA 201991607 A EA201991607 A EA 201991607A EA 201991607 A EA201991607 A EA 201991607A EA 201991607 A1 EA201991607 A1 EA 201991607A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cells
genetically modified
modified cells
natural killers
cblb
Prior art date
Application number
EA201991607A
Other languages
English (en)
Inventor
Сяокуй Чжан
Цянь Е
Тяньцзянь Ли
Чуань Ван
Мини Бхаратхан
Юри Херцберг
Роберт Дж. Хэрири
Original Assignee
Селулэрити, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Селулэрити, Инк. filed Critical Селулэрити, Инк.
Publication of EA201991607A1 publication Critical patent/EA201991607A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к генетически модифицированным (GM) клеткам-натуральным киллерам (NK), описанным в настоящем документе, и к способам получения популяций GM NK-клеток. Кроме того, изобретение относится к способам применения GM NK-клеток, описанных в настоящем документе, например, для подавления пролиферации опухолевых клеток или для ингибирования патогенной инфекции, например вирусной инфекции. В некоторых вариантах GM NK-клетки, представленные в настоящем описании, лишены экспрессии и/или функции CBLB, NKG2A и/или TGFBR2 или демонстрируют пониженную экспрессию и/или функцию CBLB, NKG2A и/или TGFBR2. В некоторых вариантах GM NK-клетки, представленные в настоящем описании, содержат модифицированный CD16.
EA201991607A 2016-12-30 2017-12-28 Генетически модифицированные клетки-натуральные киллеры EA201991607A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662440909P 2016-12-30 2016-12-30
PCT/US2017/068827 WO2018126074A1 (en) 2016-12-30 2017-12-28 Genetically modified natural killer cells

Publications (1)

Publication Number Publication Date
EA201991607A1 true EA201991607A1 (ru) 2020-01-24

Family

ID=62711057

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991607A EA201991607A1 (ru) 2016-12-30 2017-12-28 Генетически модифицированные клетки-натуральные киллеры

Country Status (10)

Country Link
US (2) US20180273903A1 (ru)
EP (1) EP3562492A4 (ru)
JP (2) JP2020503043A (ru)
CN (2) CN110913870A (ru)
AU (2) AU2017386790A1 (ru)
BR (1) BR112019013282A2 (ru)
CA (1) CA3048979A1 (ru)
EA (1) EA201991607A1 (ru)
MX (2) MX2019007840A (ru)
WO (1) WO2018126074A1 (ru)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200015469A (ko) * 2017-05-11 2020-02-12 난트케이웨스트, 인크. 항-egfr/고친화성 nk-세포 조성물 및 척색종 치료 방법
CA3100341A1 (en) * 2018-05-16 2019-11-21 Research Institute Of Nationwide Children's Hospital Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins
WO2020014245A1 (en) * 2018-07-10 2020-01-16 Nantkwest, Inc. Cryopreservation
CN109117403B (zh) * 2018-07-17 2020-07-10 武汉精测电子集团股份有限公司 一种基于serdes电路产生c_phy信号的装置
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
MX2021006208A (es) * 2018-11-28 2021-10-01 Univ Texas Edición por multiplexación del genoma de células inmunitarias para mejorar la funcionalidad y resistencia al entorno supresor.
KR20210129105A (ko) * 2019-02-15 2021-10-27 에디타스 메디신, 인코포레이티드 면역치료법을 위한 변형된 자연 살해(nk) 세포
CN110079529A (zh) * 2019-04-28 2019-08-02 成都美杰赛尔生物科技有限公司 用于靶向敲除人NKG2A/KLRC1基因的sgRNA、表达载体、试剂盒及其用途
JP7629414B2 (ja) * 2019-06-04 2025-02-13 ンカルタ・インコーポレイテッド 免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ
WO2021022229A1 (en) * 2019-07-31 2021-02-04 Celularity Inc. Populations of natural killer cells comprising a cleavage resistant cd16
BR112022009836A2 (pt) * 2019-11-20 2022-08-02 Cartherics Pty Ltd Método para fornecer células imunes com função aumentada
WO2021113849A1 (en) * 2019-12-05 2021-06-10 Celularity Inc. Her2+ cancer treatment with populations of natural killer cells comprising a cleavage resistant cd16
KR20230024984A (ko) 2020-06-12 2023-02-21 엔카르타, 인크. Cd70-지시 암 면역요법용 유전적으로 변형된 자연 살해 세포
EP4194055A4 (en) * 2020-08-07 2025-02-12 CRAGE medical Co., Limited MANIPULATED CELLS AND METHODS FOR MANIPULATING CELLS
EP4232567A1 (en) * 2020-10-26 2023-08-30 Shoreline Biosciences, Inc. Methods of inducing antibody-dependent cellular cytotoxicity (adcc) using modified natural killer (nk) cells
TW202233831A (zh) * 2020-11-03 2022-09-01 中國大陸商杭州啟函生物科技有限公司 增強免疫療法的系統和方法
IL303269A (en) 2020-12-03 2023-07-01 Century Therapeutics Inc Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AU2021401052A1 (en) 2020-12-18 2023-06-22 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
WO2022226337A1 (en) * 2021-04-22 2022-10-27 Artec Biotech, Inc. Method for producing hematopoietic cells from stem cells using vascular organoids
KR20240010717A (ko) * 2021-05-20 2024-01-24 우시 바이올로직스 아일랜드 리미티드 유전적으로 변형된 nk 세포들 및 이들의 용도
JP2024537176A (ja) * 2021-10-05 2024-10-10 サイトヴィア セラピューティクス， エルエルシー ナチュラルキラー細胞及びその使用方法
WO2023078288A1 (en) * 2021-11-03 2023-05-11 Hangzhou Qihan Biotechnology Co., Ltd. Systems and methods for enhanced immunotherapies
WO2023078287A1 (en) * 2021-11-03 2023-05-11 Hangzhou Qihan Biotechnology Co., Ltd. Systems and methods for enhanced immunotherapies
WO2023215278A1 (en) * 2022-05-03 2023-11-09 The Broad Institute, Inc. Modified immune cells and methods for use thereof
CN114921416B (zh) * 2022-05-12 2023-05-23 广东普罗凯融生物医药科技有限公司 一种nk细胞及其制备方法
CN115820645B (zh) * 2022-11-28 2023-09-22 上海恩凯细胞技术有限公司 制备沉默nkg2a基因的nk细胞的方法及其用途
WO2024199407A1 (en) * 2023-03-31 2024-10-03 Qihan Hong Kong Limited Cancer immunotherapies using engineered cells
CN116590237B (zh) * 2023-05-29 2023-10-31 上海贝斯昂科生物科技有限公司 一种遗传修饰的自然杀伤细胞及其制备和用途
WO2025029975A1 (en) * 2023-07-31 2025-02-06 Jibe Therapeutics, Inc. Compositions for redirecting immunoglobulins to immune cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ617412A (en) * 2007-09-28 2015-06-26 Anthrogenesis Corp Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
WO2009046104A1 (en) * 2007-10-01 2009-04-09 University Of Miami Aptamer-targeted sirna to prevent attenuation or suppression of t cell function
AT506041A1 (de) * 2007-12-10 2009-05-15 Univ Innsbruck Verfahren zur erhöhung der immunreaktivität
US20110280849A1 (en) * 2010-03-26 2011-11-17 Anthrogenesis Corporation Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
EP2471548A1 (de) * 2010-12-28 2012-07-04 Apeiron Biologics AG siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs
RU2019124982A (ru) * 2012-08-13 2019-09-02 Антродженезис Корпорейшн Природные клетки-киллеры и их применение
EP3622960A1 (en) * 2013-02-05 2020-03-18 Celularity, Inc. Natural killer cells from placenta
US11311575B2 (en) * 2013-05-13 2022-04-26 Cellectis Methods for engineering highly active T cell for immunotherapy
AU2014278323B2 (en) * 2013-06-10 2020-05-28 Dana-Farber Cancer Institute, Inc. Methods and compositions for reducing immunosupression by tumor cells
US10144770B2 (en) * 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
WO2015148926A1 (en) * 2014-03-28 2015-10-01 Regents Of The University Of Minnesota Polypeptides, cells, and methods involving engineered cd16
CA2945335A1 (en) * 2014-04-18 2015-10-22 Editas Medicine, Inc. Crispr-cas-related methods, compositions and components for cancer immunotherapy
CA2959318A1 (en) * 2014-08-28 2016-03-03 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations
EA201791443A1 (ru) * 2014-12-31 2018-01-31 Антродженезис Корпорейшн Естественные киллерные клетки и их применения
EP3317399B1 (en) * 2015-06-30 2024-06-26 Cellectis Methods for improving functionality in nk cell by gene inactivation using specific endonuclease

Also Published As

Publication number Publication date
CN118813544A (zh) 2024-10-22
JP2023036648A (ja) 2023-03-14
CN110913870A (zh) 2020-03-24
AU2017386790A1 (en) 2019-07-18
AU2024205408A1 (en) 2024-08-22
CA3048979A1 (en) 2018-07-05
MX2024002353A (es) 2024-03-14
BR112019013282A2 (pt) 2019-12-17
JP2020503043A (ja) 2020-01-30
US20220348875A1 (en) 2022-11-03
MX2019007840A (es) 2020-08-03
EP3562492A4 (en) 2020-12-09
WO2018126074A1 (en) 2018-07-05
EP3562492A1 (en) 2019-11-06
US20180273903A1 (en) 2018-09-27

Similar Documents

Publication Publication Date Title
EA201991607A1 (ru) Генетически модифицированные клетки-натуральные киллеры
PH12019501557A1 (en) Bacillus isolates and uses thereof
WO2018190719A3 (en) Anti-sirp alpha antibodies
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
WO2018237148A8 (en) Multispecific antibodies that target hiv gp120 and cd3
EA201992155A1 (ru) Способы криогенного хранения
WO2018234793A3 (en) Antibodies
MY191649A (en) Antibodies to tigit
EA201890960A1 (ru) Натуральные киллеры и клетки ilc3 и их применение
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
MX2018002999A (es) Composiciones de inoculante estables y metodos para producir las mismas.
PH12017500915A1 (en) Cd47 antibodies, methods, and uses
ZA202201874B (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
EA201791443A1 (ru) Естественные киллерные клетки и их применения
NZ737796A (en) Anti-tau antibodies and methods of use
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
EA201790413A1 (ru) Антитела против tigit
JOP20200016B1 (ar) أجسام مضادة لـ cd137
PH12019500643A1 (en) Antibodies that bind interleukin-2 and uses thereof
EA201890572A1 (ru) Биофармацевтические композиции
PH12020551948A1 (en) Monospecific and multispecific anti-tmeff2 antibodies and their uses
MX2019010101A (es) Composiciones y metodos para promover el crecimiento del cabello con inhibidores de mpc1.
MX2024005649A (es) Proteinas quimericas basadas en sirp1a y cd40l.
EA202190197A1 (ru) Лечение язвенного колита с помощью бразикумаба
EA202090971A1 (ru) Способы применения и композиции, содержащие дулаглутид